NEWS DETAIL

Contract Award

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a further contract by existing client Merck KGaA (“Merck”) that it expects to be completed over the next two to three months.  This contract follows on from and is additional to the initial tranche of projects with Merck announced on 17 December 2020, with a value of £270k, intended to be completed in the first six to eight months of calendar year 2021.  As has been its practice since 2019, Merck has awarded contracts to Physiomics in November or December to cover the first two to three quarters of the following calendar year and then extended these or awarded new contracts during the course of the year.  The contract announced today represents the first such extension and others will be announced as and when they are agreed.

Enquiries:

Physiomics plc                                                  
Dr Jim Millen, CEO
44 (0)1865 784 980

Hybridan LLP (broker)
Claire Louise Noyce
44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company’s Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics’ technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.